Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
26.18
+0.16 (0.61%)
At close: Jan 22, 2026, 4:00 PM EST
26.18
0.00 (0.00%)
After-hours: Jan 22, 2026, 4:33 PM EST
Immunovant Market Cap
Immunovant has a market cap or net worth of $5.31 billion as of January 22, 2026. Its market cap has increased by 45.70% in one year.
Market Cap
5.31B
Enterprise Value
4.79B
1-Year Change
45.70%
Ranking
Category
Stock Price
$26.18
Market Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $5.31B, an increase of 4,166.22%. That is a compound annual growth rate of 76.72%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 21, 2026 | 5.27B | 2.36% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 929.76B |
| Johnson & Johnson | 526.82B |
| AbbVie | 378.84B |
| UnitedHealth Group | 299.85B |
| AstraZeneca | 289.32B |
| Novartis AG | 278.23B |
| Merck & Co. | 270.12B |
| Novo Nordisk | 261.50B |